Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.

Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O'Dwyer PJ.

Clin Cancer Res. 2013 May 1;19(9):2541-50. doi: 10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26.

2.

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.

Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA.

Clin Cancer Res. 2013 May 15;19(10):2745-54. doi: 10.1158/1078-0432.CCR-12-3177. Epub 2013 Feb 26.

3.

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L.

Eur J Cancer. 2013 Jan;49(2):312-22. doi: 10.1016/j.ejca.2012.08.005. Epub 2012 Sep 3.

PMID:
22954665
4.

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

Clark JJ, Cools J, Curley DP, Yu JC, Lokker NA, Giese NA, Gilliland DG.

Blood. 2004 Nov 1;104(9):2867-72. Epub 2004 Jul 15.

5.

PDGF C is a selective alpha platelet-derived growth factor receptor agonist that is highly expressed in platelet alpha granules and vascular smooth muscle.

Fang L, Yan Y, Komuves LG, Yonkovich S, Sullivan CM, Stringer B, Galbraith S, Lokker NA, Hwang SS, Nurden P, Phillips DR, Giese NA.

Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):787-92.

PMID:
15061151
7.

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA.

Cancer Cell. 2002 Jun;1(5):421-32.

9.

Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.

Matsuno K, Ichimura M, Nakajima T, Tahara K, Fujiwara S, Kase H, Ushiki J, Giese NA, Pandey A, Scarborough RM, Lokker NA, Yu JC, Irie J, Tsukuda E, Ide S, Oda S, Nomoto Y.

J Med Chem. 2002 Jul 4;45(14):3057-66.

PMID:
12086491
10.

Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.

Yu JC, Lokker NA, Hollenbach S, Apatira M, Li J, Betz A, Sedlock D, Oda S, Nomoto Y, Matsuno K, Ide S, Tsukuda E, Giese NA.

J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8.

11.

RP-1776, a novel cyclic peptide produced by Streptomyces sp., inhibits the binding of PDGF to the extracellular domain of its receptor.

Toki S, Agatsuma T, Ochiai K, Saitoh Y, Ando K, Nakanishi S, Lokker NA, Giese NA, Matsuda Y.

J Antibiot (Tokyo). 2001 May;54(5):405-14.

12.

PDGF-D, a new protease-activated growth factor.

LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS.

Nat Cell Biol. 2001 May;3(5):517-21.

PMID:
11331882
13.

RP-1551s, a family of azaphilones produced by Penicillium sp., inhibit the binding of PDGF to the extracellular domain of its receptor.

Toki S, Tanaka T, Uosaki Y, Yoshida M, Suzuki Y, Kita K, Mihara A, Ando K, Lokker NA, Giese NA, Matsuda Y.

J Antibiot (Tokyo). 1999 Mar;52(3):235-44.

14.

Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution.

Ultsch M, Lokker NA, Godowski PJ, de Vos AM.

Structure. 1998 Nov 15;6(11):1383-93.

15.
17.
19.
20.

Purification and characterization of natural human interleukin-3.

Zenke G, Lokker NA, Strittmatter U, Fagg B, Geisse S, Huber-Wegmann G, Kocher HP.

Lymphokine Cytokine Res. 1991 Aug;10(4):329-35.

PMID:
1932378
21.

Structure-activity relationship study of human interleukin-3: role of the C-terminal region for biological activity.

Lokker NA, Zenke G, Strittmatter U, Fagg B, Movva NR.

EMBO J. 1991 Aug;10(8):2125-31.

22.
23.

Mapping the epitopes of neutralizing anti-human IL-3 monoclonal antibodies. Implications for structure-activity relationship.

Lokker NA, Strittmatter U, Steiner C, Fagg B, Graff P, Kocher HP, Zenke G.

J Immunol. 1991 Feb 1;146(3):893-8.

PMID:
1703185

Supplemental Content

Loading ...
Support Center